Aptinyx Raises $70 Million in Series B Financing to Advance Growing Pipeline through Clinical Studies in Neurologic Disorders by mparnell | Dec 18, 2017 | Portfolio News
Aptinyx Bolsters Executive Leadership Team with Appointment of Andy Kidd as Chief Commercial Officer by mparnell | Dec 7, 2017 | Portfolio News
Aptinyx Granted Fast Track Designation, Initiates Phase 1 for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder by mparnell | Dec 7, 2017 | Portfolio News
Collegium to License Rights to Commercialize Nucynta Franchise by mparnell | Dec 4, 2017 | Portfolio News
Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer by mparnell | Dec 4, 2017 | Portfolio News
